Paper39440707
Enrichment for clinical trials of early AD: Combining genetic risk factors and plasma p-tau as screening instruments.
Wang X and 6 others. Alzheimers Dement, 2024. Cited by 4 papers, by iCite.
Cite this record
ConductScience Library. Enrichment for clinical trials of early AD: Combining genetic risk factors and plasma p-tau as screening instruments. Papers, record 39440707. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39440707
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Alzheimer Disease | Major topic |
| tau Proteins | Major topic |
| Cognitive Dysfunction | Major topic |
| Humans | |
| Female | |
| Male | |
| Aged | |
| Risk Factors | |
| Clinical Trials as Topic | |
| Biomarkers | |
| Disease Progression | |
| Phosphorylation | |
| Aged, 80 and over |
Source PubMed
Grants6
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| U01 AG024904 | NIA NIH HHS | United States | U01AG024904 | PubMed and NIH | NIH RePORTER |
| P30 AG062429 | NIA NIH HHS | United States | P30AG062429 | PubMed | NIH RePORTER |
| R25 NS117367 | NINDS NIH HHS | United States | R25NS117367 | PubMed | NIH RePORTER |
| R01 AG080663 | NIA NIH HHS | United States | R01AG080663 | PubMed and NIH | NIH RePORTER |
| R01 AG066088 | NIA NIH HHS | United States | R01AG066088 | PubMed and NIH | NIH RePORTER |
| 1R01AG066088 | NIH HHS | United States | R01AG066088 | PubMed and NIH | NIH RePORTER |
References25
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36927491 | Plasma phospho-tau in Alzheimer's disease: towards diagnostic and therapeutic trial applications. | Mol Neurodegener | 2023 | https://conductscience.org/library/papers/36927491 | PubMed |
| 2 | 37012068 | Plasma phosphorylated tau 181 predicts amyloid status and conversion to dementia stage dependent on renal function. | J Neurol Neurosurg Psychiatry | 2023 | https://conductscience.org/library/papers/37012068 | PubMed |
| 3 | 36745413 | Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers. | JAMA Neurol | 2023 | https://conductscience.org/library/papers/36745413 | PubMed |
| 4 | 33491853 | The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease. | Alzheimers Dement | 2021 | https://conductscience.org/library/papers/33491853 | PubMed |
| 5 | 36878697 | Potential Utility of Plasma P-Tau and Neurofilament Light Chain as Surrogate Biomarkers for Preventive Clinical Trials. | Neurology | 2023 | https://conductscience.org/library/papers/36878697 | PubMed |
| 6 | 34180956 | Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging. | JAMA Neurol | 2021 | https://conductscience.org/library/papers/34180956 | PubMed |
| 7 | 24211008 | Operationalizing hippocampal volume as an enrichment biomarker for amnestic mild cognitive impairment trials: effect of algorithm, test-retest variability, and cut point on trial cost, duration, and sample size. | Neurobiol Aging | 2014 | https://conductscience.org/library/papers/24211008 | PubMed |
| 8 | 26379620 | Fluid Biomarkers in Clinical Trials of Alzheimer's Disease Therapeutics. | Front Neurol | 2015 | https://conductscience.org/library/papers/26379620 | PubMed |
| 9 | 29177679 | Polygenic hazard score: an enrichment marker for Alzheimer's associated amyloid and tau deposition. | Acta Neuropathol | 2018 | https://conductscience.org/library/papers/29177679 | PubMed |
| 10 | 36701211 | A simple genetic stratification method for lower cost, more expedient clinical trials in early Alzheimer's disease: A preliminary study of tau PET and cognitive outcomes. | Alzheimers Dement | 2023 | https://conductscience.org/library/papers/36701211 | PubMed |
| 11 | 33249783 | Plasma phosphorylated tau181 and neurodegeneration in Alzheimer's disease. | Ann Clin Transl Neurol | 2021 | https://conductscience.org/library/papers/33249783 | PubMed |
| 12 | 22796873 | Enriching amnestic mild cognitive impairment populations for clinical trials: optimal combination of biomarkers to predict conversion to dementia. | J Alzheimers Dis | 2012 | https://conductscience.org/library/papers/22796873 | PubMed |
| 13 | 35379951 | Early-stage Alzheimer disease: getting trial-ready. | Nat Rev Neurol | 2022 | https://conductscience.org/library/papers/35379951 | PubMed |
| 14 | 39440707 | Enrichment for clinical trials of early AD: Combining genetic risk factors and plasma p-tau as screening instruments. | Alzheimers Dement | 2024 | https://conductscience.org/library/papers/39440707 | PubMed |
| 15 | 33580752 | TOMM40-APOE haplotypes are associated with cognitive decline in non-demented Blacks. | Alzheimers Dement | 2021 | https://conductscience.org/library/papers/33580752 | PubMed |
| 16 | 35496374 | Clinical application of CSF biomarkers for Alzheimer's disease: From rationale to ratios. | Alzheimers Dement (Amst) | 2022 | https://conductscience.org/library/papers/35496374 | PubMed |
| 17 | 27558378 | Enrichment of clinical trials in MCI due to AD using markers of amyloid and neurodegeneration. | Neurology | 2016 | https://conductscience.org/library/papers/27558378 | PubMed |
| 18 | 32999917 | Enriching the design of Alzheimer's disease clinical trials: Application of the polygenic hazard score and composite outcome measures. | Alzheimers Dement (N Y) | 2020 | https://conductscience.org/library/papers/32999917 | PubMed |
| 19 | 28721928 | Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. | Lancet Neurol | 2017 | https://conductscience.org/library/papers/28721928 | PubMed |
| 20 | 37694991 | The potential clinical value of plasma biomarkers in Alzheimer's disease. | Alzheimers Dement | 2023 | https://conductscience.org/library/papers/37694991 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42818907 | Rare extreme polygenic risk scores strongly indicate Alzheimer's disease risk. | medRxiv | 2026 | https://conductscience.org/library/papers/42818907 | PubMed |
| 42325556 | A dual space MRI radiomic network signature for risk stratification and subtyping of mild cognitive impairment. | iScience | 2026 | https://conductscience.org/library/papers/42325556 | PubMed |
| 41988903 | Clinical impact of the Alzheimer's Disease Neuroimaging Initiative: A review of studies using ADNI data (2023 to June 2025). | Alzheimers Dement | 2026 | https://conductscience.org/library/papers/41988903 | PubMed |
| 39440707 | Enrichment for clinical trials of early AD: Combining genetic risk factors and plasma p-tau as screening instruments. | Alzheimers Dement | 2024 | https://conductscience.org/library/papers/39440707 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| MAPT | 4137 | PubTator's text mining | https://conductscience.org/library/genes/4137 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39440707
GET https://conductscience.org/api/papers/v1/39440707/references?page=2